| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.851 | 0.003 | 0.851 | Cholinergic | 0.289 0.02 DBMET03285 | ||
| 0.827 | 0.003 | 0.827 | Acetylcholinesterase inhibitor | 0.172 0.043 DBMET03285 | ||
| 0.797 | 0.003 | 0.797 | Butyrylcholinesterase inhibitor | 0.191 0.023 DBMET03285 | ||
| 0.649 | 0.006 | 0.649 | Amyloid beta aggregation inhibitor | 0.342 0.036 DBMET03285 | ||
| 0.636 | 0.006 | 0.636 | Apoptosis antagonist | 0.597 0.01 DBMET03285 | ||
| 0.58 | 0.004 | 0.58 | Chelator | 0.567 0.004 DBMET03285 | ||
| 0.522 | 0.017 | 0.522 | Nootropic | 0.21 0.145 DBMET03285 | ||
| 0.47 | 0.008 | 0.47 | MAO inhibitor | 0.22 0.035 DBMET03285 | ||
| 0.425 | 0.023 | 0.425 | DNA damaging | 0.409 0.027 DBMET03285 | ||
| 0.391 | 0.03 | 0.391 | Antiamyloidogenic | 0.189 0.107 DBMET03285 | ||
| 0.348 | 0.01 | 0.348 | Cholinergic antagonist | 0.188 0.035 DBMET03285 | ||
| 0.346 | 0.011 | 0.346 | MAO A inhibitor | 0.154 0.04 DBMET03285 | ||
| 0.343 | 0.01 | 0.343 | MAO B inhibitor | 0.145 0.039 DBMET03285 | ||
| 0.331 | 0.005 | 0.331 | Raf kinase C inhibitor | |||
| 0.389 | 0.067 | 0.607 | GABA C receptor rho-3 antagonist | 0.607 0.007 DBMET03285 | DBMET03285 | |
| 0.331 | 0.011 | 0.331 | Acetylcholine antagonist | 0.178 0.037 DBMET03285 | ||
| 0.295 | 0.007 | 0.295 | Acetylcholine nicotinic antagonist | 0.164 0.017 DBMET03285 | ||
| 0.282 | 0.018 | 0.282 | Acetylcholine M1 receptor antagonist | 0.2 0.042 DBMET03285 | ||
| 0.34 | 0.113 | 0.34 | Analgesic | 0.236 0.196 DBMET03285 | ||
| 0.225 | 0.005 | 0.225 | Amidase inhibitor | 0.074 0.043 DBMET03285 | ||
| 0.21 | 0.004 | 0.21 | MAP kinase kinase 1 inhibitor | 0.154 0.015 DBMET03285 | ||
| 0.225 | 0.02 | 0.225 | MAP kinase kinase inhibitor | 0.144 0.055 DBMET03285 | ||
| 0.249 | 0.05 | 0.368 | RNA-directed DNA polymerase inhibitor | 0.368 0.022 DBMET03285 | DBMET03285 | |
| 0.228 | 0.029 | 0.228 | 5 Hydroxytryptamine 3E antagonist | 0.212 0.045 DBMET03285 | ||
| 0.214 | 0.023 | 0.214 | Alkylator | 0.15 0.047 DBMET03285 | ||
| 0.194 | 0.003 | 0.194 | LIM domain kinase 2 inhibitor | |||
| 0.26 | 0.079 | 0.293 | Antioxidant | 0.293 0.064 DBMET03285 | DBMET03285 | |
| 0.18 | 0.009 | 0.18 | Neuronal nicotinic receptor antagonist | 0.108 0.021 DBMET03285 | ||
| 0.229 | 0.062 | 0.229 | Platelet aggregation inhibitor | 0.146 0.133 DBMET03285 | ||
| 0.19 | 0.029 | 0.269 | DNA intercalator | 0.269 0.014 DBMET03285 | DBMET03285 | |
| 0.273 | 0.112 | 0.374 | Vasodilator, peripheral | 0.374 0.064 DBMET03285 | DBMET03285 | |
| 0.159 | 0.005 | 0.297 | Kallikrein inhibitor | 0.297 0.004 DBMET03285 | DBMET03285 | |
| 0.232 | 0.081 | 0.273 | DNA synthesis inhibitor | 0.273 0.054 DBMET03285 | DBMET03285 | |
| 0.185 | 0.037 | 0.293 | Cell wall synthesis inhibitor | 0.293 0.01 DBMET03285 | DBMET03285 | |
| 0.178 | 0.031 | 0.178 | Acetylcholine muscarinic antagonist | 0.115 0.072 DBMET03285 | ||
| 0.325 | 0.181 | 0.405 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | 0.405 0.096 DBMET03285 | DBMET03285 | |
| 0.148 | 0.004 | 0.296 | Plasma kallikrein inhibitor | 0.296 0.004 DBMET03285 | DBMET03285 | |
| 0.208 | 0.066 | 0.296 | Glyceraldehyde-3-phosphate dehydrogenase inhibitor | 0.296 0.025 DBMET03285 | DBMET03285 | |
| 0.206 | 0.068 | 0.338 | Platelet adhesion inhibitor | 0.338 0.023 DBMET03285 | DBMET03285 | |
| 0.139 | 0.004 | 0.155 | Factor XIa inhibitor | 0.155 0.004 DBMET03285 | DBMET03285 | |
| 0.138 | 0.004 | 0.172 | Factor XI inhibitor | 0.172 0.004 DBMET03285 | DBMET03285 | |
| 0.156 | 0.024 | 0.156 | Acetylcholine agonist | 0.083 0.063 DBMET03285 | ||
| 0.244 | 0.112 | 0.32 | Ca2+/calmodulin-dependent kinase II alpha inhibitor | 0.32 0.051 DBMET03285 | DBMET03285 | |
| 0.136 | 0.005 | 0.136 | Oleamide hydrolase inhibitor | |||
| 0.192 | 0.067 | 0.192 | LIM domain kinase 1 inhibitor | |||
| 0.215 | 0.096 | 0.215 | Tumour necrosis factor alpha release inhibitor | |||
| 0.227 | 0.108 | 0.43 | 5 Hydroxytryptamine uptake stimulant | 0.43 0.01 DBMET03285 | DBMET03285 | |
| 0.222 | 0.106 | 0.287 | 5 Hydroxytryptamine 1E antagonist | 0.287 0.039 DBMET03285 | DBMET03285 | |
| 0.188 | 0.081 | 0.249 | Anesthetic general | 0.249 0.051 DBMET03285 | DBMET03285 | |
| 0.11 | 0.007 | 0.11 | Nicotinic receptor alpha4 subunit antagonist | 0.062 0.021 DBMET03285 | ||
| 0.112 | 0.01 | 0.112 | Nicotinic receptor alpha7 subunit antagonist | 0.06 0.028 DBMET03285 | ||
| 0.25 | 0.148 | 0.25 | Toll-Like receptor 7 agonist | |||
| 0.132 | 0.031 | 0.197 | Prolactin inhibitor | 0.197 0.009 DBMET03285 | DBMET03285 | |
| 0.121 | 0.02 | 0.121 | 5 Hydroxytryptamine uptake inhibitor | |||
| 0.139 | 0.039 | 0.139 | TRPA1 agonist | |||
| 0.123 | 0.025 | 0.123 | Acetylcholine nicotinic agonist | 0.089 0.047 DBMET03285 | ||
| 0.14 | 0.042 | 0.143 | Falcipain 3 inhibitor | 0.143 0.04 DBMET03285 | DBMET03285 | |
| 0.1 | 0.003 | 0.1 | Benzodiazepine receptor peripheral-type antagonist | |||
| 0.231 | 0.139 | 0.321 | Cholesterol antagonist | 0.321 0.078 DBMET03285 | DBMET03285 | |
| 0.243 | 0.155 | 0.243 | Toll-Like receptor agonist | |||
| 0.09 | 0.004 | 0.09 | Benzodiazepine antagonist | |||
| 0.137 | 0.052 | 0.137 | Platelet activating factor antagonist | |||
| 0.107 | 0.026 | 0.107 | Nicotinic alpha4beta2 receptor antagonist | 0.104 0.028 DBMET03285 | ||
| 0.126 | 0.047 | 0.126 | Nav1.5 sodium channel blocker | |||
| 0.091 | 0.016 | 0.123 | Glutamate (mGluR7) antagonist | 0.123 0.004 DBMET03285 | DBMET03285 | |
| 0.077 | 0.008 | 0.077 | Cholesterol esterase inhibitor | |||
| 0.145 | 0.08 | 0.234 | GABA C receptor rho-2 antagonist | 0.234 0.015 DBMET03285 | DBMET03285 | |
| 0.11 | 0.045 | 0.126 | Interleukin 1 beta converting enzyme inhibitor | 0.126 0.03 DBMET03285 | DBMET03285 | |
| 0.102 | 0.038 | 0.102 | Bromodomain-containing protein 2 inhibitor | 0.09 0.056 DBMET03285 | ||
| 0.17 | 0.107 | 0.17 | Insulin sensitizer | 0.162 0.117 DBMET03285 | ||
| 0.071 | 0.009 | 0.071 | Integrin alpha4 antagonist | |||
| 0.167 | 0.106 | 0.167 | Antimitotic | 0.148 0.124 DBMET03285 | ||
| 0.069 | 0.008 | 0.087 | Geranyltranstransferase inhibitor | 0.087 0.004 DBMET03285 | DBMET03285 | |
| 0.141 | 0.082 | 0.141 | MAP kinase 3 inhibitor | 0.13 0.107 DBMET03285 | ||
| 0.134 | 0.076 | 0.134 | Histone deacetylase SIRT1 inhibitor | |||
| 0.138 | 0.08 | 0.177 | Ca2+-transporting ATPase inhibitor | 0.177 0.008 DBMET03285 | DBMET03285 | |
| 0.144 | 0.086 | 0.252 | Anticoagulant | 0.252 0.038 DBMET03285 | DBMET03285 | |
| 0.123 | 0.064 | 0.123 | Beta amyloid protein antagonist | |||
| 0.197 | 0.14 | 0.367 | Tyrosine 3 hydroxylase inhibitor | 0.367 0.013 DBMET03285 | DBMET03285 | |
| 0.181 | 0.125 | 0.288 | Nitric-oxide synthase stimulant | 0.288 0.015 DBMET03285 | DBMET03285 | |
| 0.104 | 0.05 | 0.104 | Protein kinase (Mos, Mil/Raf, MEKK, RIPK, TESK, LIMK, IRAK, ILK, Activin/TGF-beta) inhibitor | |||
| 0.063 | 0.013 | 0.063 | Dopamine D3 agonist | |||
| 0.09 | 0.041 | 0.098 | Caspase 7 inhibitor | 0.098 0.03 DBMET03285 | DBMET03285 | |
| 0.131 | 0.083 | 0.149 | Protein kinase stimulant | 0.149 0.069 DBMET03285 | DBMET03285 | |
| 0.127 | 0.079 | 0.174 | Bone formation stimulant | 0.174 0.044 DBMET03285 | DBMET03285 | |
| 0.05 | 0.004 | 0.05 | Nicotinic alpha4beta2 receptor agonist | 0.041 0.007 DBMET03285 | ||
| 0.085 | 0.041 | 0.085 | Acetylcholine M4 receptor antagonist | |||
| 0.14 | 0.096 | 0.15 | CF transmembrane conductance regulator agonist | 0.15 0.076 DBMET03285 | DBMET03285 | |
| 0.107 | 0.064 | 0.112 | Topoisomerase I inhibitor | 0.112 0.061 DBMET03285 | DBMET03285 | |
| 0.123 | 0.08 | 0.123 | Vanilloid 1 agonist | |||
| 0.112 | 0.07 | 0.112 | Microtubule formation inhibitor | 0.109 0.075 DBMET03285 | ||
| 0.134 | 0.094 | 0.161 | Adenylate cyclase stimulant | 0.161 0.045 DBMET03285 | DBMET03285 | |
| 0.167 | 0.127 | 0.204 | Free radical scavenger | 0.204 0.095 DBMET03285 | DBMET03285 | |
| 0.049 | 0.012 | 0.049 | 2,3-Oxidosqualene-lanosterol cyclase inhibitor | |||
| 0.086 | 0.049 | 0.12 | Estrogen-related receptor beta agonist | 0.12 0.01 DBMET03285 | DBMET03285 | |
| 0.163 | 0.128 | 0.576 | Aldehyde oxidase inhibitor | 0.576 0.022 DBMET03285 | DBMET03285 | |
| 0.202 | 0.167 | 0.335 | Transcription factor NF kappa B inhibitor | 0.335 0.082 DBMET03285 | DBMET03285 | |
| 0.131 | 0.097 | 0.157 | Pregnane X receptor agonist | 0.157 0.042 DBMET03285 | DBMET03285 | |
| 0.097 | 0.064 | 0.097 | Sphingomyelinase inhibitor | 0.096 0.064 DBMET03285 | ||
| 0.055 | 0.024 | 0.055 | Dopamine D2 agonist | |||
| 0.079 | 0.049 | 0.132 | CYP2A6 inhibitor | 0.132 0.022 DBMET03285 | DBMET03285 | |
| 0.175 | 0.146 | 0.517 | 5 Hydroxytryptamine release stimulant | 0.517 0.025 DBMET03285 | DBMET03285 | |
| 0.04 | 0.012 | 0.04 | Adenosine uptake inhibitor | |||
| 0.032 | 0.007 | 0.032 | Vanilloid 2 agonist | 0.025 0.019 DBMET03285 | ||
| 0.045 | 0.02 | 0.045 | Vascular adhesion protein 1 inhibitor | |||
| 0.089 | 0.065 | 0.109 | Glutamate release inhibitor | 0.109 0.031 DBMET03285 | DBMET03285 | |
| 0.035 | 0.012 | 0.035 | NMDA 2D receptor antagonist | |||
| 0.057 | 0.036 | 0.057 | Acetylcholine muscarinic agonist | |||
| 0.082 | 0.062 | 0.159 | D-Ala-D-Ala ligase inhibitor | 0.159 0.005 DBMET03285 | DBMET03285 | |
| 0.223 | 0.203 | 0.42 | Antibacterial | 0.42 0.068 DBMET03285 | DBMET03285 | |
| 0.099 | 0.079 | 0.132 | Protein kinase C gamma inhibitor | 0.132 0.043 DBMET03285 | DBMET03285 | |
| 0.029 | 0.011 | 0.029 | Acid ceramidase inhibitor | 0.027 0.015 DBMET03285 | ||
| 0.062 | 0.043 | 0.062 | Acetylcholine M2 receptor antagonist | |||
| 0.096 | 0.082 | 0.308 | Cystathionine beta-synthase inhibitor | 0.308 0.009 DBMET03285 | DBMET03285 | |
| 0.064 | 0.05 | 0.064 | Acetylcholine M5 receptor agonist | |||
| 0.058 | 0.045 | 0.058 | Phosphodiesterase 1A inhibitor | |||
| 0.043 | 0.03 | 0.043 | Acetylcholine M1 receptor agonist | |||
| 0.131 | 0.118 | 0.184 | Heat shock protein 70 antagonist | 0.184 0.01 DBMET03285 | DBMET03285 | |
| 0.128 | 0.116 | 0.192 | Arachidonic acid antagonist | 0.192 0.04 DBMET03285 | DBMET03285 | |
| 0.019 | 0.008 | 0.019 | Nicotinic alpha4 receptor agonist | 0.016 0.011 DBMET03285 | ||
| 0.03 | 0.02 | 0.038 | Nicotinic alpha3beta4 receptor agonist | 0.038 0.012 DBMET03285 | DBMET03285 | |
| 0.046 | 0.039 | 0.082 | Dopamine beta hydroxylase inhibitor | 0.082 0.005 DBMET03285 | DBMET03285 | |
| 0.098 | 0.091 | 0.138 | Acetylcholine release stimulant | 0.138 0.025 DBMET03285 | DBMET03285 | |
| 0.114 | 0.108 | 0.286 | Cytidine deaminase inhibitor | 0.286 0.021 DBMET03285 | DBMET03285 | |
| 0.057 | 0.054 | 0.085 | Dopamine D1 antagonist | 0.085 0.03 DBMET03285 | DBMET03285 | |
| 0.134 | 0.131 | 0.249 | Pyruvate kinase inhibitor | 0.249 0.061 DBMET03285 | DBMET03285 | |
| 0.054 | 0.052 | 0.054 | TRPA1 antagonist | |||
| 0.064 | 0.061 | 0.064 | Raf kinase inhibitor | |||
| 0.058 | 0.056 | 0.058 | Protease 3C (Human rhinovirus) inhibitor | |||
| 0.081 | 0.08 | 0.081 | Platelet activating factor alpha antagonist | |||
| 0.051 | 0.054 | 0.088 | Carbamoyl phosphate synthetase inhibitor | 0.088 0.025 DBMET03285 | DBMET03285 | |
| 0.133 | 0.136 | 0.138 | 3C-like protease (Human coronavirus) inhibitor | 0.138 0.123 DBMET03285 | DBMET03285 | |
| 0.178 | 0.182 | 0.223 | Gastrin inhibitor | 0.223 0.114 DBMET03285 | DBMET03285 | |
| 0.072 | 0.077 | 0.125 | Histamine N-methyltransferase inhibitor | 0.125 0.027 DBMET03285 | DBMET03285 | |
| 0.135 | 0.144 | 0.24 | Succinate dehydrogenase inhibitor | 0.24 0.026 DBMET03285 | DBMET03285 | |
| 0.076 | 0.085 | 0.124 | Triose-phosphate isomerase inhibitor | 0.124 0.03 DBMET03285 | DBMET03285 | |
| 0.024 | 0.036 | 0.041 | Estrogen-related receptor gamma antagonist | 0.041 0.005 DBMET03285 | DBMET03285 | |
| 0.185 | 0.196 | 0.24 | Vasodilator, coronary | 0.24 0.144 DBMET03285 | DBMET03285 | |
| 0.081 | 0.093 | 0.247 | GABA C receptor agonist | 0.247 0.014 DBMET03285 | DBMET03285 | |
| 0.045 | 0.06 | 0.103 | Mannitol-1-phosphate 5-dehydrogenase inhibitor | 0.103 0.014 DBMET03285 | DBMET03285 | |
| 0.048 | 0.065 | 0.09 | Cyclin D1 inhibitor | 0.09 0.012 DBMET03285 | DBMET03285 | |
| 0.039 | 0.056 | 0.047 | mTOR inhibitor | 0.047 0.043 DBMET03285 | DBMET03285 | |
| 0.034 | 0.052 | 0.056 | Nerve growth factor antagonist | 0.056 0.012 DBMET03285 | DBMET03285 | |
| 0.102 | 0.123 | 0.512 | Peroxidase inhibitor | 0.512 0.009 DBMET03285 | DBMET03285 | |
| 0.043 | 0.065 | 0.054 | Nicotinic alpha3beta2 receptor antagonist | 0.054 0.034 DBMET03285 | DBMET03285 | |
| 0.152 | 0.175 | 0.172 | Hypoglycemic | 0.172 0.144 DBMET03285 | DBMET03285 | |
| 0.092 | 0.115 | 0.253 | Alpha-N-acetylglucosaminidase inhibitor | 0.253 0.022 DBMET03285 | DBMET03285 | |
| 0.035 | 0.058 | 0.042 | Adenylate cyclase 1 inhibitor | 0.042 0.038 DBMET03285 | DBMET03285 | |
| 0.075 | 0.1 | 0.193 | UDP-glucose 4-epimerase inhibitor | 0.193 0.019 DBMET03285 | DBMET03285 | |
| 0.048 | 0.075 | 0.093 | 5 Hydroxytryptamine 3 agonist | 0.093 0.019 DBMET03285 | DBMET03285 | |
| 0.109 | 0.136 | 0.127 | Heat shock protein 90 antagonist | 0.127 0.102 DBMET03285 | DBMET03285 | |
| 0.038 | 0.067 | 0.077 | Aconitate hydratase inhibitor | 0.077 0.015 DBMET03285 | DBMET03285 | |
| 0.193 | 0.224 | 0.288 | Calcium channel activator | 0.288 0.104 DBMET03285 | DBMET03285 | |
| 0.05 | 0.081 | 0.112 | Catalase inhibitor | 0.112 0.035 DBMET03285 | DBMET03285 | |
| 0.237 | 0.27 | 0.465 | Caspase 9 stimulant | 0.465 0.075 DBMET03285 | DBMET03285 | |
| 0.037 | 0.071 | 0.055 | Topoisomerase II beta inhibitor | 0.055 0.026 DBMET03285 | DBMET03285 | |
| 0.07 | 0.106 | 0.29 | Creatine kinase inhibitor | 0.29 0.004 DBMET03285 | DBMET03285 | |
| 0.035 | 0.071 | 0.062 | Acyl-CoA dehydrogenase inhibitor | 0.062 0.032 DBMET03285 | DBMET03285 | |
| 0.033 | 0.07 | 0.053 | CF transmembrane conductance regulator antagonist | 0.053 0.006 DBMET03285 | DBMET03285 | |
| 0.075 | 0.113 | 0.152 | GABA C receptor rho-1 antagonist | 0.152 0.021 DBMET03285 | DBMET03285 | |
| 0.022 | 0.061 | 0.036 | 1-Alkyl-2-acetylglycerophosphocholine esterase inhibitor | 0.036 0.021 DBMET03285 | DBMET03285 | |
| 0.035 | 0.074 | 0.06 | Glucose-6-phosphate isomerase inhibitor | 0.06 0.019 DBMET03285 | DBMET03285 | |
| 0.05 | 0.09 | 0.077 | Protein kinase C beta inhibitor | 0.077 0.035 DBMET03285 | DBMET03285 | |
| 0.079 | 0.12 | 0.131 | Adenylate kinase inhibitor | 0.131 0.035 DBMET03285 | DBMET03285 | |
| 0.023 | 0.065 | 0.078 | Alpha 1d adrenoreceptor agonist | 0.078 0.005 DBMET03285 | DBMET03285 | |
| 0.071 | 0.113 | 0.133 | Carbonic anhydrase III inhibitor | 0.133 0.036 DBMET03285 | DBMET03285 | |
| 0.023 | 0.066 | 0.039 | Ceramide glucosyltransferase inhibitor | 0.039 0.019 DBMET03285 | DBMET03285 | |
| 0.048 | 0.091 | 0.082 | Ryanodine receptor antagonist | 0.082 0.008 DBMET03285 | DBMET03285 | |
| 0.182 | 0.227 | 0.413 | Histamine release inhibitor | 0.413 0.069 DBMET03285 | DBMET03285 | |
| 0.094 | 0.139 | 0.166 | Antibacterial (Helicobacter pylori) | 0.166 0.035 DBMET03285 | DBMET03285 | |
| 0.034 | 0.079 | 0.214 | Alcohol oxidase inhibitor | 0.214 0.006 DBMET03285 | DBMET03285 | |
| 0.085 | 0.131 | 0.118 | Cyclooxygenase 3 inhibitor | 0.118 0.08 DBMET03285 | DBMET03285 | |
| 0.046 | 0.093 | 0.266 | Porphobilinogen synthase inhibitor | 0.266 0.007 DBMET03285 | DBMET03285 | |
| 0.088 | 0.137 | 0.158 | Toll-Like receptor 9 antagonist | 0.158 0.058 DBMET03285 | DBMET03285 | |
| 0.07 | 0.124 | 0.117 | Anabolic | 0.117 0.042 DBMET03285 | DBMET03285 | |
| 0.044 | 0.1 | 0.085 | Enoyl-[acyl-carrier-protein] reductase inhibitor | 0.085 0.016 DBMET03285 | DBMET03285 | |
| 0.07 | 0.127 | 0.181 | 5 Hydroxytryptamine 3A agonist | 0.181 0.021 DBMET03285 | DBMET03285 | |
| 0.01 | 0.07 | 0.018 | Estrogen-related receptor gamma agonist | 0.018 0.014 DBMET03285 | DBMET03285 | |
| 0.081 | 0.142 | 0.179 | Aldehyde dehydrogenase inhibitor | 0.179 0.034 DBMET03285 | DBMET03285 | |
| 0.162 | 0.226 | 0.271 | Insulysin inhibitor | 0.271 0.078 DBMET03285 | DBMET03285 | |
| 0.082 | 0.146 | 0.184 | Lipid peroxidase inhibitor | 0.184 0.049 DBMET03285 | DBMET03285 | |
| 0.049 | 0.115 | 0.061 | Transcription factor RelA inhibitor | 0.061 0.05 DBMET03285 | DBMET03285 | |
| 0.064 | 0.132 | 0.183 | Ferrochelatase inhibitor | 0.183 0.027 DBMET03285 | DBMET03285 | |
| 0.101 | 0.168 | 0.156 | Psychostimulant | 0.156 0.111 DBMET03285 | DBMET03285 | |
| 0.034 | 0.103 | 0.102 | NMDA 2 receptor antagonist | 0.102 0.031 DBMET03285 | DBMET03285 | |
| 0.064 | 0.133 | 0.129 | DNA directed RNA polymerase inhibitor | 0.129 0.032 DBMET03285 | DBMET03285 | |
| 0.034 | 0.104 | 0.113 | Phosphofructokinase-1 inhibitor | 0.113 0.027 DBMET03285 | DBMET03285 | |
| 0.04 | 0.111 | 0.083 | Na+ K+ transporting ATPase inhibitor | 0.083 0.048 DBMET03285 | DBMET03285 | |
| 0.07 | 0.142 | 0.16 | GABA C receptor antagonist | 0.16 0.025 DBMET03285 | DBMET03285 | |
| 0.018 | 0.094 | 0.047 | Oxytocin agonist | 0.047 0.026 DBMET03285 | DBMET03285 | |
| 0.071 | 0.147 | 0.116 | Tubulin antagonist | 0.116 0.084 DBMET03285 | DBMET03285 | |
| 0.031 | 0.107 | 0.059 | Alpha-mannosidase inhibitor | 0.059 0.028 DBMET03285 | DBMET03285 | |
| 0.061 | 0.138 | 0.133 | NADH dehydrogenase inhibitor | 0.133 0.023 DBMET03285 | DBMET03285 | |
| 0.027 | 0.106 | 0.055 | 3-Hydroxyanthranilate 3,4-dioxygenase inhibitor | 0.055 0.01 DBMET03285 | DBMET03285 | |
| 0.018 | 0.098 | 0.026 | Hedgehog signaling activator | 0.026 0.023 DBMET03285 | DBMET03285 | |
| 0.091 | 0.172 | 0.118 | DNA repair enzyme inhibitor | 0.118 0.077 DBMET03285 | DBMET03285 | |
| 0.075 | 0.156 | 0.105 | Photosensitizer | 0.105 0.079 DBMET03285 | DBMET03285 | |
| 0.032 | 0.114 | 0.046 | Squalene epoxidase inhibitor | 0.046 0.043 DBMET03285 | DBMET03285 | |
| 0.021 | 0.104 | 0.045 | Adenosine A2b receptor antagonist | 0.045 0.04 DBMET03285 | DBMET03285 | |
| 0.027 | 0.11 | 0.046 | Kainate receptor agonist | 0.046 0.02 DBMET03285 | DBMET03285 | |
| 0.065 | 0.149 | 0.11 | Cholesterol synthesis inhibitor | 0.11 0.076 DBMET03285 | DBMET03285 | |
| 0.063 | 0.147 | 0.102 | Protein kinase C zeta inhibitor | 0.102 0.048 DBMET03285 | DBMET03285 | |
| 0.045 | 0.131 | 0.094 | Glutamate dehydrogenase inhibitor | 0.094 0.034 DBMET03285 | DBMET03285 | |
| 0.035 | 0.123 | 0.052 | 5 Hydroxytryptamine 7 agonist | 0.052 0.049 DBMET03285 | DBMET03285 | |
| 0.04 | 0.128 | 0.123 | NAD(P)H dehydrogenase (quinone) inhibitor | 0.123 0.028 DBMET03285 | DBMET03285 | |
| 0.034 | 0.123 | 0.156 | Phenylalanine 4-hydroxylase inhibitor | 0.156 0.011 DBMET03285 | DBMET03285 | |
| 0.015 | 0.104 | 0.028 | Purinergic P2Y15 antagonist | 0.028 0.02 DBMET03285 | DBMET03285 | |
| 0.021 | 0.111 | 0.032 | Protein kinase (CK2) beta inhibitor | 0.032 0.027 DBMET03285 | DBMET03285 | |
| 0.045 | 0.134 | 0.115 | HIV-1 integrase inhibitor | 0.115 0.017 DBMET03285 | DBMET03285 | |
| 0.061 | 0.151 | 0.104 | Granulocyte macrophage colony stimulating factor agonist | 0.104 0.03 DBMET03285 | DBMET03285 | |
| 0.047 | 0.139 | 0.07 | S-adenosyl-L-methionine decarboxylase inhibitor | 0.07 0.06 DBMET03285 | DBMET03285 | |
| 0.069 | 0.16 | 0.108 | Phosphodiesterase 6D inhibitor | 0.108 0.038 DBMET03285 | DBMET03285 | |
| 0.02 | 0.113 | 0.046 | Mannosidase inhibitor | 0.046 0.03 DBMET03285 | DBMET03285 | |
| 0.042 | 0.136 | 0.102 | Telomerase inhibitor | 0.102 0.032 DBMET03285 | DBMET03285 | |
| 0.013 | 0.107 | 0.032 | Fumarate hydratase inhibitor | 0.032 0.027 DBMET03285 | DBMET03285 | |
| 0.052 | 0.147 | 0.121 | Alcohol dehydrogenase inhibitor | 0.121 0.034 DBMET03285 | DBMET03285 | |
| 0.008 | 0.105 | 0.026 | Cyclin E2 inhibitor | 0.026 0.022 DBMET03285 | DBMET03285 | |
| 0.09 | 0.189 | 0.155 | Cyclin-dependent kinase 8 inhibitor | 0.155 0.074 DBMET03285 | DBMET03285 | |
| 0.027 | 0.127 | 0.078 | Biliverdin reductase inhibitor | 0.078 0.027 DBMET03285 | DBMET03285 | |
| 0.026 | 0.128 | 0.042 | GABA B receptor antagonist | 0.042 0.03 DBMET03285 | DBMET03285 | |
| 0.036 | 0.141 | 0.084 | Heat shock protein 90 beta antagonist | 0.084 0.018 DBMET03285 | DBMET03285 | |
| 0.018 | 0.128 | 0.046 | Aldose reductase inhibitor | 0.046 0.043 DBMET03285 | DBMET03285 | |
| 0.027 | 0.136 | 0.049 | Glutamate (mGluR group III) antagonist | 0.049 0.023 DBMET03285 | DBMET03285 | |
| 0.035 | 0.144 | 0.113 | Glutamate decarboxylase inhibitor | 0.113 0.023 DBMET03285 | DBMET03285 | |
| 0.007 | 0.123 | 0.025 | Uridine phosphorylase inhibitor | 0.025 0.022 DBMET03285 | DBMET03285 | |
| 0.03 | 0.146 | 0.072 | Fatty acid synthase inhibitor | 0.072 0.024 DBMET03285 | DBMET03285 | |
| 0.035 | 0.156 | 0.083 | Aminopeptidase I inhibitor | 0.083 0.039 DBMET03285 | DBMET03285 | |
| 0.054 | 0.176 | 0.089 | MAP kinase kinase 7 inhibitor | 0.089 0.027 DBMET03285 | DBMET03285 | |
| 0.081 | 0.203 | 0.119 | Sphingosine 1-phosphate receptor 2 agonist | 0.119 0.057 DBMET03285 | DBMET03285 | |
| 0.181 | 0.304 | 0.335 | Apoptosis agonist | 0.335 0.148 DBMET03285 | DBMET03285 | |
| 0.07 | 0.195 | 0.127 | Toll-Like receptor antagonist | 0.127 0.075 DBMET03285 | DBMET03285 | |
| 0.015 | 0.14 | 0.058 | Dopamine D5 agonist | 0.058 0.013 DBMET03285 | DBMET03285 | |
| 0.021 | 0.148 | 0.037 | Glutamate (mGluR8) agonist | 0.037 0.029 DBMET03285 | DBMET03285 | |
| 0.103 | 0.232 | 0.233 | Neurotrophic factor enhancer | 0.233 0.049 DBMET03285 | DBMET03285 | |
| 0.021 | 0.15 | 0.058 | Argininosuccinate synthase inhibitor | 0.058 0.039 DBMET03285 | DBMET03285 | |
| 0.19 | 0.325 | 0.348 | 5 Hydroxytryptamine release inhibitor | 0.348 0.117 DBMET03285 | DBMET03285 | |
| 0.011 | 0.146 | 0.06 | Estradiol 17 beta-dehydrogenase inhibitor | 0.06 0.02 DBMET03285 | DBMET03285 | |
| 0.054 | 0.19 | 0.104 | Lanosterol 14 alpha demethylase inhibitor | 0.104 0.049 DBMET03285 | DBMET03285 | |
| 0.052 | 0.189 | 0.1 | Bile acid receptor antagonist | 0.1 0.049 DBMET03285 | DBMET03285 | |
| 0.048 | 0.187 | 0.073 | Vanilloid 4 agonist | 0.073 0.057 DBMET03285 | DBMET03285 | |
| 0.046 | 0.185 | 0.16 | HIV-1 integrase (Overall Integration) inhibitor | 0.16 0.022 DBMET03285 | DBMET03285 | |
| 0.058 | 0.198 | 0.11 | Carbonic anhydrase XV inhibitor | 0.11 0.056 DBMET03285 | DBMET03285 | |
| 0.013 | 0.153 | 0.049 | Carbonic anhydrase VB inhibitor | 0.049 0.046 DBMET03285 | DBMET03285 | |
| 0.016 | 0.156 | 0.052 | Adenosine deaminase inhibitor | 0.052 0.029 DBMET03285 | DBMET03285 | |
| 0.109 | 0.25 | 0.191 | Cyclic AMP phosphodiesterase inhibitor | 0.191 0.101 DBMET03285 | DBMET03285 | |
| 0.027 | 0.169 | 0.145 | Histidine decarboxylase inhibitor | 0.145 0.02 DBMET03285 | DBMET03285 | |
| 0.053 | 0.196 | 0.078 | mTOR complex 2 inhibitor | 0.078 0.075 DBMET03285 | DBMET03285 | |
| 0.055 | 0.199 | 0.111 | Mucolytic | 0.111 0.064 DBMET03285 | DBMET03285 | |
| 0.033 | 0.177 | 0.061 | Pregnane X receptor antagonist | 0.061 0.028 DBMET03285 | DBMET03285 | |
| 0.062 | 0.206 | 0.14 | DOPA decarboxylase inhibitor | 0.14 0.027 DBMET03285 | DBMET03285 | |
| 0.006 | 0.151 | 0.022 | Estradiol 17 beta-dehydrogenase 1 inhibitor | 0.022 0.016 DBMET03285 | DBMET03285 | |
| 0.075 | 0.219 | 0.139 | Transcription factor STAT6 inhibitor | 0.139 0.033 DBMET03285 | DBMET03285 | |
| 0.042 | 0.187 | 0.086 | Keratolytic | 0.086 0.041 DBMET03285 | DBMET03285 | |
| 0.047 | 0.192 | 0.076 | Glutathione S-transferase inhibitor | 0.076 0.069 DBMET03285 | DBMET03285 | |
| 0.063 | 0.209 | 0.127 | Activin receptor-like kinase 2 inhibitor | 0.127 0.088 DBMET03285 | DBMET03285 | |
| 0.049 | 0.197 | 0.104 | UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor | 0.104 0.051 DBMET03285 | DBMET03285 | |
| 0.112 | 0.264 | 0.337 | Superoxide dismutase inhibitor | 0.337 0.04 DBMET03285 | DBMET03285 | |
| 0.01 | 0.163 | 0.041 | Catechol O-methyltransferase inhibitor | 0.041 0.013 DBMET03285 | DBMET03285 | |
| 0.023 | 0.177 | 0.311 | NMDA 2B receptor antagonist | 0.311 0.004 DBMET03285 | DBMET03285 | |
| 0.038 | 0.193 | 0.104 | Aminopeptidase B inhibitor | 0.104 0.062 DBMET03285 | DBMET03285 | |
| 0.076 | 0.231 | 0.163 | Mannose-6-phosphate isomerase inhibitor | 0.163 0.054 DBMET03285 | DBMET03285 | |
| 0.052 | 0.211 | 0.119 | Electrolyte absorption antagonist | 0.119 0.037 DBMET03285 | DBMET03285 | |
| 0.042 | 0.206 | 0.104 | Topoisomerase II inhibitor | 0.104 0.082 DBMET03285 | DBMET03285 | |
| 0.06 | 0.227 | 0.139 | Toll-Like receptor 2 antagonist | 0.139 0.06 DBMET03285 | DBMET03285 | |
| 0.06 | 0.229 | 0.126 | NADPH oxidase inhibitor | 0.126 0.076 DBMET03285 | DBMET03285 | |
| 0.004 | 0.174 | 0.022 | Nicotinic acid receptor 1 antagonist | 0.022 0.007 DBMET03285 | DBMET03285 | |
| 0.084 | 0.255 | 0.162 | Immunostimulant | 0.162 0.145 DBMET03285 | DBMET03285 | |
| 0.045 | 0.217 | 0.077 | GABA B receptor agonist | 0.077 0.05 DBMET03285 | DBMET03285 | |
| 0.029 | 0.201 | 0.07 | Purinergic P2X1 antagonist | 0.07 0.032 DBMET03285 | DBMET03285 | |
| 0.034 | 0.205 | 0.091 | Macrophage migration inhibitory factor inhibitor | 0.091 0.04 DBMET03285 | DBMET03285 | |
| 0.036 | 0.209 | 0.07 | Adenosine A3 receptor antagonist | 0.07 0.059 DBMET03285 | DBMET03285 | |
| 0.021 | 0.195 | 0.068 | HIV-1 reverse transcriptase inhibitor | 0.068 0.051 DBMET03285 | DBMET03285 | |
| 0.102 | 0.277 | 0.173 | Neurotensin receptor agonist | 0.173 0.059 DBMET03285 | DBMET03285 | |
| 0.042 | 0.225 | 0.062 | Prolactin release inhibitor | 0.062 0.043 DBMET03285 | DBMET03285 | |
| 0.077 | 0.264 | 0.133 | Hemostatic | 0.133 0.09 DBMET03285 | DBMET03285 | |
| 0.083 | 0.271 | 0.153 | Interferon gamma antagonist | 0.153 0.074 DBMET03285 | DBMET03285 | |
| 0.118 | 0.307 | 0.205 | Antithrombotic | 0.205 0.171 DBMET03285 | DBMET03285 | |
| 0.076 | 0.265 | 0.144 | I kappa B kinase epsilon inhibitor | 0.144 0.126 DBMET03285 | DBMET03285 | |
| 0.034 | 0.227 | 0.058 | Phosphodiesterase 1C inhibitor | 0.058 0.055 DBMET03285 | DBMET03285 | |
| 0.036 | 0.229 | 0.071 | Carbonic anhydrase VI inhibitor | 0.071 0.07 DBMET03285 | DBMET03285 | |
| 0.027 | 0.222 | 0.134 | Monophenol monooxygenase inhibitor | 0.134 0.054 DBMET03285 | DBMET03285 | |
| 0.024 | 0.221 | 0.05 | CXC chemokine 1 receptor antagonist | 0.05 0.037 DBMET03285 | DBMET03285 | |
| 0.091 | 0.291 | 0.148 | Phospholipase C inhibitor | 0.148 0.111 DBMET03285 | DBMET03285 | |
| 0.076 | 0.278 | 0.152 | Melanin inhibitor | 0.152 0.079 DBMET03285 | DBMET03285 | |
| 0.035 | 0.241 | 0.081 | Glycine receptor agonist | 0.081 0.038 DBMET03285 | DBMET03285 | |
| 0.034 | 0.241 | 0.09 | Expectorant | 0.09 0.081 DBMET03285 | DBMET03285 | |
| 0.068 | 0.284 | 0.154 | MAP kinase kinase 2 inhibitor | 0.154 0.118 DBMET03285 | DBMET03285 | |
| 0.064 | 0.291 | 0.168 | DNA methyltransferase I inhibitor | 0.168 0.088 DBMET03285 | DBMET03285 | |
| 0.053 | 0.281 | 0.086 | CC chemokine 5 receptor agonist | 0.086 0.046 DBMET03285 | DBMET03285 | |
| 0.096 | 0.324 | 0.129 | CC chemokine 6 receptor antagonist | 0.129 0.076 DBMET03285 | DBMET03285 | |
| 0.019 | 0.246 | 0.06 | 3(or 17)beta-hydroxysteroid dehydrogenase inhibitor | 0.06 0.029 DBMET03285 | DBMET03285 | |
| 0.024 | 0.252 | 0.068 | Topoisomerase II alpha inhibitor | 0.068 0.063 DBMET03285 | DBMET03285 | |
| 0.008 | 0.241 | 0.065 | Nicotinic acid receptor agonist | 0.065 0.01 DBMET03285 | DBMET03285 | |
| 0.022 | 0.258 | 0.084 | NMDA receptor antagonist | 0.084 0.06 DBMET03285 | DBMET03285 | |
| 0.059 | 0.3 | 0.146 | Heat shock protein 90 alpha antagonist | 0.146 0.09 DBMET03285 | DBMET03285 | |
| 0.082 | 0.326 | 0.136 | Lipocortins synthesis antagonist | 0.136 0.128 DBMET03285 | DBMET03285 | |
| 0.053 | 0.301 | 0.109 | Interleukin 8 antagonist | 0.109 0.078 DBMET03285 | DBMET03285 | |
| 0.06 | 0.318 | 0.225 | Interleukin agonist | 0.225 0.099 DBMET03285 | DBMET03285 | |
| 0.107 | 0.381 | 0.184 | Peptidyltransferase inhibitor | 0.184 0.122 DBMET03285 | DBMET03285 | |
| 0.059 | 0.339 | 0.159 | DNA methylase inhibitor | 0.159 0.11 DBMET03285 | DBMET03285 | |
| 0.064 | 0.346 | 0.167 | Non-steroidal antiinflammatory agent | 0.167 0.097 DBMET03285 | DBMET03285 | |
| 0.006 | 0.296 | 0.033 | Estradiol 17 beta-dehydrogenase 2 inhibitor | 0.033 0.026 DBMET03285 | DBMET03285 | |
| 0.012 | 0.311 | 0.032 | Estrogen-related receptor beta antagonist | 0.032 0.023 DBMET03285 | DBMET03285 | |
| 0.036 | 0.345 | 0.154 | Aryl hydrocarbon receptor agonist | 0.154 0.133 DBMET03285 | DBMET03285 | |
| 0.092 | 0.414 | 0.292 | Sodium/bile acid cotransporter inhibitor | 0.292 0.087 DBMET03285 | DBMET03285 | |
| 0.011 | 0.333 | 0.063 | Phosphatidylinositol 3-kinase gamma inhibitor | 0.063 0.029 DBMET03285 | DBMET03285 | |
| 0.075 | 0.405 | 0.226 | Hypoxia-inducible factor 1 alpha inhibitor | 0.226 0.122 DBMET03285 | DBMET03285 | |
| 0.03 | 0.364 | 0.09 | Beta glucuronidase inhibitor | 0.09 0.089 DBMET03285 | DBMET03285 | |
| 0.045 | 0.381 | 0.181 | Glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase inhibitor | 0.181 0.112 DBMET03285 | DBMET03285 | |
| 0.015 | 0.351 | 0.065 | MAP3K7 inhibitor | 0.065 0.063 DBMET03285 | DBMET03285 | |
| 0.047 | 0.41 | 0.134 | Hexokinase inhibitor | 0.134 0.099 DBMET03285 | DBMET03285 | |
| 0.046 | 0.423 | 0.12 | Sphingosine 1-phosphate receptor 2 antagonist | 0.12 0.098 DBMET03285 | DBMET03285 | |
| 0.064 | 0.444 | 0.124 | Sphingosine 1-phosphate receptor 5 antagonist | 0.124 0.115 DBMET03285 | DBMET03285 | |
| 0.05 | 0.435 | 0.145 | Hepatoprotectant | 0.145 0.115 DBMET03285 | DBMET03285 | |
| 0.037 | 0.512 | 0.187 | 12-Lipoxygenase inhibitor | 0.187 0.166 DBMET03285 | DBMET03285 | |
| 0.013 | 0.536 | 0.111 | CDC-like kinase 1 inhibitor | 0.111 0.105 DBMET03285 | DBMET03285 | |
| 0.07 | 0.614 | 0.515 | Antiinflammatory | 0.515 0.081 DBMET03285 | DBMET03285 | |
| 0.004 | 0.577 | 0.241 | Nicotinic acid receptor 2 agonist | 0.241 0.003 DBMET03285 | DBMET03285 | |
| 0.007 | 0.63 | 0.103 | Glutamate receptor antagonist | 0.103 0.093 DBMET03285 | DBMET03285 | |
| 0.009 | 0.653 | 0.122 | Dual specificity tyrosine-phosphorylation regulated kinase 1B inhibitor | 0.122 0.105 DBMET03285 | DBMET03285 | |
| 0.06 | 0.74 | 0.238 | Interleukin 2 agonist | 0.238 0.133 DBMET03285 | DBMET03285 | |
| 0.006 | 0.802 | 0.123 | Estrogen antagonist | 0.123 0.049 DBMET03285 | DBMET03285 | |
| 0.004 | 0.911 | 0.119 | Estrogen receptor beta antagonist | 0.119 0.033 DBMET03285 | DBMET03285 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |